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Abstract
Background: Patients with diabetes already fulfill one diagnostic criterion for MS according to the
existing classifications. Our aim was to identify one single clinical parameter, which could effectively
predict the presence of MS in patients with type 2 diabetes.
Methods: We studied all patients with type 2 diabetes who attended our Diabetes Outpatient
Clinic during a three-month period. Waist circumference, blood pressure and serum lipids were
measured. Establishment of MS diagnosis was based a) on National Cholesterol Education Program
Adult Treatment Panel III (NCEP ATP III) criteria and b) on International Diabetes Federation (IDF)
criteria. Receiver operating characteristic (ROC) analysis was applied in order to identify the
clinical parameter with the highest predictive capability for MS. Among the 500 participating
patients (231 males, 269 females), MS was diagnosed in 364 patients (72.8%) according to the NCEP
ATP III criteria and in 408 patients (81.6%) according to the IDF criteria.
Results: For the NCEP ATP III classification, serum triglycerides (in the overall population), waist
and HDL (in female population) demonstrated the highest predictive capability for MS
(AUCs:0.786, 0.805 and 0.801, respectively). For the IDF classification, no single parameter reached
an AUC > 0.800 in the overall population. In females, HDL displayed a satisfactory predictive
capability for MS with an AUC which was significantly higher than the one in males (0.785 vs. 0.676,
respectively, p < 0.05).
Conclusion: Elevated serum triglycerides strongly indicate the presence of MS in patients with
type 2 diabetes. In female patients with type 2 diabetes, central obesity was the second stronger
predictor of MS besides hypertriglyceridemia.
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Background
Patients with the metabolic syndrome (MS) are at
increased risk of coronary heart disease and other cardio-
vascular diseases related to plaque buildups in artery walls
(e.g., stroke and peripheral vascular disease) [1]. Moreo-
ver MS also increases mortality from both cardiovascular
disease and all causes [2,3]. Patients with type 2 diabetes
already fulfill one of the NCEP ATP III or IDF diagnostic
criteria, while at least two more are required for the con-
firmation of NCEP ATP III/M.S diagnosis, and necessarily
abdominal obesity plus one additional criterion for the
IDF/MS diagnosis [4,5]. Several studies have investigated
the role of each of the metabolic syndrome components
in modifying cardiovascular risk in patients with type 2
diabetes [6].
Our study aimed in identifying a single parameter – of
those used for diagnosing MS according to NCEP ATP III
and IDF classifications – which could predict the presence
of the syndrome in patients with type 2 diabetes.
Research design and methods
We studied all patients with type 2 diabetes who attended
our Diabetes Outpatient Clinic during a three-month
period in 2004. Pregnant females were excluded from the
study. Waist circumference, systolic (SBP) and diastolic
(DBP) blood pressure were measured, body mass index
(BMI) was estimated and blood samples were drawn for
serum lipids measurement after a 12-hour fast. Establish-
ment of MS diagnosis was based: a) on NCEP ATP III cri-
teria [4] and b) on IDF criteria [5]. The study was
approved by the ethical review committee of our hospital.
All patients gave an informed consent.
According to the NCEP ATP III classification, MS is
defined as the presence of three or more of the following
criteria: 1) increased waist circumference (>102 cm in
males, >88 cm in females), 2) elevated serum triglycerides
(≥150 mg/dl), 3) low HDL cholesterol (<40 mg/dl in
males, <50 mg/dl in females), 4) hypertension (SBP ≥130
mmHg and/or DBP ≥85 mmHg) or medical treatment of
previously diagnosed hypertension and 5) impaired fast-
ing glucose (≥110 mg/dl). According to the new IDF defi-
nition, diagnosis of MS requires central obesity (defined as
waist circumference ≥94 cm for Europid men and ≥80 cm
for Europid women, with ethnicity specific values for
other groups) plus any two of the following: 1) elevated
serum triglycerides (≥150 mg/dl) or specific treatment for
this lipid abnormality, 2) low HDL cholesterol (<40 mg/
dl in males, <50 mg/dl in females) or specific treatment
for this lipid abnormality, 3) hypertension (SBP ≥130
mmHg and/or DBP ≥85 mmHg) or medical treatment for
previously diagnosed hypertension and 4) high fasting
plasma glucose (≥100 mg/dl) or previously diagnosed
type 2 diabetes.
We created receiver operating characteristics (ROC) curves
of serum triglycerides, HDL, SBP, DBP and waist circum-
ference for the prediction of MS and we used the areas
under the corresponding curves (area under the curve,
AUC) to evaluate the predictive efficiency of each MS
parameter. Statistical analysis was performed with SPSS
10.0 (1999, Chicago, IL). Statistical significance was set at
a level of p < 0.05. Variables with AUCs≥0.800 were con-
sidered as having satisfactory predictive capability for the
presence of MS. We used the algorithms of Hanley and
McNeil for comparison of AUCs derived from different
samples [7] or from the same sample [8]. The critical level
for the z statistic was set at 1.96. We also tried different
cutoffs in the selected variables and estimated the corre-
sponding sensitivity (SENS), specificity (SPEC), positive
predictive value (PPV) and negative predictive value
(NPV). Serum HDL and waist circumference were ana-
lyzed according to gender, since the cutoffs used in the
two definitions for these variables are different in males
and females.
Results
500 patients (231 males and 269 females) were enrolled
in the study. Metabolic syndrome was diagnosed in 364
patients (72.8%) according to the NCEP ATP III criteria
and in 408 patients (81.6%) according to the IDF criteria.
The concordance between the two classifications was
moderate (kappa = 0.640, p < 0.001). 10 (2.7%) of the
364 patients diagnosed with MS according to the NCEP
ATP III classification did not fulfill the IDF criteria for MS,
while 54 (13.2%) of the 408 patients diagnosed with MS
according to the IDF classification did not fulfill the NCEP
ATP III criteria for MS. After stratification by gender, 213
females (79.1%) and 151 males (65.4%) had MS accord-
ing to the NCEP ATP III classification (p = 0.001), while
232 females (86.2%) and 176 males (76.2%) had MS
according to the IDF classification (p = 0.004). Demo-
graphic and other characteristics of the patients with MS
vs. those without MS according to the two classifications
are shown in table 1.
For the NCEP ATP III classification, serum triglycerides in
the overall population, and waist circumference and HDL
in females had the highest predictive ability for MS
(AUCs: 0.786, 0.805 and 0.801, respectively). After strati-
fication by gender, the AUC for triglycerides differed sig-
nificantly (0.843 in females vs. 0.744 in males, z = 2.47, p
< 0.05). In younger patients (<50 years old), AUC for
serum triglycerides was 0.811 [95% confidence intervals
(CI) 0.685–0.939, p < 0.001]. In females, serum triglycer-
ide level was a stronger predictor of MS than waist circum-
ference (0.843 vs. 0.805, respectively), but the difference
did not reach statistical significance (z = 0.82, p = NS).Cardiovascular Diabetology 2006, 5:21 http://www.cardiab.com/content/5/1/21
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We have calculated SENS, SPEC, PPV, and NPV at differ-
ent cutoffs for triglycerides (in the overall population)
and for waist and HDL in females, to assess the specificity
for MS diagnosis according to the NCEP ATP III classifica-
tion (Table 2). We aimed at cutoffs with satisfactory spe-
cificity (≥70%) for MS diagnosis [9], but with a
reasonably acceptable sensitivity (>60%) as well. The esti-
mated PPVs were high, while the NPVs were low, as
expected from the high prevalence of the syndrome in our
patient population. A cutoff of 120 mg/dl for serum trig-
lycerides showed a satisfactory SPEC (70%), while a
higher cutoff of 140 mg/dl had an even higher SPEC
(88%). Serum HDL cutoffs of 55 and 50 mg/dl showed
SPEC (66% and 93%, respectively). A waist cutoff of 98
cm in females showed 72% SPEC and a higher cutoff of
100 cm had similar SPEC (75%). In the majority (73.3%)
of females with waist >98 cm, hypertension was the crite-
rion which accomplished the MS diagnosis, while in
nearly all females with HDL <50 mg/dl or triglycerides
>150 mg/dl (97.3% and 98.0%, respectively), MS diagno-
sis was accomplished by the waist criterion.
For the IDF classification, in the overall population, no
single parameter reached an AUC≥0.800. In females,
serum HDL displayed the highest predictive capability for
MS with an AUC which was significantly higher than the
one in males (0.785 vs. 0.676, respectively, p < 0.05).
However, HDL cutoffs above the suggested 50 mg/dl cut-
off in females exhibited SPEC lower than 70% (table 3).
The AUC for triglycerides was higher in females compared
to males (0.803 vs. 0.719), as with the NCEP ATP III clas-
sification, but the observed difference did not reach statis-
tical significance. However, serum triglycerides above the
150 mg/dl cutoff in the overall population and HDL
below the 50 mg/dl cutoff in females had 100% SPEC and
100% PPV, since patients with diabetes, central obesity (a
prerequisite risk factor for IDF MS) plus one lipid criterion
fulfill three IDF criteria.
Discussion
Patients with type 2 diabetes have higher cardiovascular
risk than non-diabetic subjects, independently of other
risk factors such as smoking, hypertension or hypercho-
lesterolemia [10]. Moreover, the prevalence of coronary
heart disease in diabetic patients increases significantly
with the addition of MS components [6].
Prevalence of MS in patients with type 2 diabetes is con-
siderably high (70–92%), as reported by several studies
using either NCEP ATP III or World Health Organization
(WHO) criteria [6,11-15]. In our patient population, the
estimated prevalence of MS was similarly high as expected
(72.8% based on the NCEP ATP III criteria and 81.6%
based on the IDF criteria).
The identification of patients with MS among patients
with type 2 diabetes is of great importance, since this pop-
ulation carries a cluster of cardiovascular risk factors and
should be urged to show major compliance to their ther-
apeutic regimen. The recognition of a single parameter
with high efficiency in predicting MS in patients with type
2 diabetes was the primary aim of our study. ROC curves
are commonly adopted in order to determine the predic-
tive ability of various methods or parameters used for the
Table 1: Demographic, clinical and laboratory data of the patients
Variable MS according to NCEP-ATP III criteria MS according to IDF criteria
With MS (n = 364) Without MS (n = 136) p value With MS (n = 419) Without MS (n = 81) p value
Age (years)* 65.9 ± 10.0 62.0 ± 12.9 0.002 65.6 ± 10.2 61.6 ± 13.6 0.010
Diabetes duration 
(years)
12.7 ± 8.4 11.5 ± 8.5 0.166 12.5 ± 8.3 11.7 ± 8.9 0.389
BMI (kg/m2) 30.0 ± 5.2 26.7 ± 4.3 <0.001 29.9 ± 5.0 25.9 ± 4.8 <0.001
Waist (cm) males 108 ± 11 98 ± 9 <0.001 107 ± 10 95 ± 11 <0.001
Waist (cm) females 105 ± 9 89 ± 17 <0.001 104 ± 10 89 ± 20 <0.001
Serum HDL (mg/d) 
males
42 ± 10 51 ± 11 <0.001 44 ± 11 51 ± 12 <0.001
Serum HDL (mg/dl) 
females
49 ± 10 61 ± 10 <0.001 50 ± 11 61 ± 10 <0.001
Serum triglycerides 
(mg/dl)
172 ± 91 106 ± 50 <0.001 164 ± 90 111 ± 57 <0.001
SBP (mmHg) 134 ± 19 126 ± 14 <0.001 134 ± 19 123 ± 11 <0.001
DBP (mmHg) 79 ± 11 75 ± 8 <0.001 79 ± 11 74 ± 6 <0.001
Glycosylated 
hemoglobin (%)
7.1 ± 1.3 7.0 ± 1.3 0.137 7.1 ± 1.3 7.0 ± 1.3 0.416Cardiovascular Diabetology 2006, 5:21 http://www.cardiab.com/content/5/1/21
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confirmation of a disease, a clinical characteristic or an
outcome.
In the overall population, serum triglycerides had a satis-
factory predictive ability for NCEP ATP III MS, while for
the IDF classification, no single parameter reached an
AUC≥0.800. Serum triglycerides in females displayed the
highest AUCs in both classifications. The predictive ability
of triglycerides for the NCEP ATP III MS was higher in
females compared to males, while for the IDF MS a similar
difference did not reach statistical significance. Serum
HDL proved to be useful in females for both classifica-
tions, but its predictive ability in males was not satisfac-
tory. A serum HDL lower than 50 mg/dl in females with
diabetes (HDL criterion fulfilled) predicted the presence
of the whole syndrome with a specificity of 92%.
Furthermore, measurement of waist circumference
although easily performed in every clinical setting (hospi-
tal, outpatient clinic, home), proved to be more useful in
females than in males. A waist circumference of 98 cm in
females with diabetes has been proved sufficient in pre-
dicting the presence of MS according to the NCEP ATP III
classification.
Limitations
There were several limitations in our study. The popula-
tion sample was not so large as to yield statistically signif-
icant results for small differences between AUCs [7]. In
particular, differences between clinical parameters in the
same set of patients (e.g. serum triglycerides vs. waist cir-
cumference in females) should be tested with larger sam-
ples to minimize the possibility of type II error. In
addition, our population sample was a selected one, since
it consisted of patients who were regularly followed up in
an outpatient clinic. It would be interesting to apply the
same method in patients with recently diagnosed diabetes
or in patients with incidentally diagnosed diabetes from a
random population sample.
Nevertheless, the information retrieved from our study
implies that a female with type 2 diabetes and central
obesity most probably has the entire MS according to the
NCEP ATP III classification.
Conclusion
Elevated serum triglyceride level was the strongest single
predictor which effectively indicated the presence of MS in
both male and female patients with type 2 diabetes
according to the NCEP ATP III classification. In female
patients with type 2 diabetes, central obesity as implied by
an increased waist circumference was the second stronger
predictor of MS after hypertriglyceridemia.
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